ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE1 DEFICIENCY
Clinical trials for ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE1 DEFICIENCY explained in plain language.
Never miss a new study
Get alerted when new ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE1 DEFICIENCY trials appear
Sign up with your email to follow new studies for ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE1 DEFICIENCY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug offers hope for babies with rare, deadly artery disease
Disease control Recruiting nowThis study tests a new medicine called INZ-701 in babies up to 1 year old who have a rare genetic condition called ENPP1 deficiency. The condition causes severe hardening of the arteries and rickets. The goal is to see if the medicine can raise a key substance in the blood, impro…
Matched conditions: ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE1 DEFICIENCY
Phase: PHASE3 • Sponsor: Inozyme Pharma • Aim: Disease control
Last updated May 26, 2026 10:41 UTC
-
New hope for babies with rare calcification diseases: drug trial launches
Disease control Recruiting nowThis early-stage study tests a new medicine called INZ-701 in up to 16 infants (up to 1 year old) who have rare genetic conditions that cause dangerous calcium buildup in blood vessels and bones. The main goal is to check if the drug is safe and how it affects the body, especiall…
Matched conditions: ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE1 DEFICIENCY
Phase: PHASE1 • Sponsor: Inozyme Pharma • Aim: Disease control
Last updated May 26, 2026 10:38 UTC